I was 22 and physically unable to go to school, to work, to even maintain a healthy social life. It was like God had pressed a pause button on my life, my hopes, my dreams. I felt stuck, unable to progress, unable to have any amount of control of my life—in the present and even in the future. What was I to do?
More LDS Church Features
On July 19, the Church released a three-part series of Mormon Messages based around the life and struggles and spiritual insights of Sister Reyna Aburto of the Relief Society General Presidency. She has experienced everything from a devastating earthquake to divorce to civil unrest in her country and seeing the way she has processed and learned from these experiences is a lesson to us all. Here is her story in text and video.
Lately I've been in a spiritual slump. Day after day the spiritual feelings haven't come. My last few visits to the temple have been pleasant, but no more. When I read the scriptures no spiritual reassurance brings tears of joy. What can I make of this “spiritually barren desert” time? Previous insights offer possible answers.
In 1873, a Greek Orthodox bishop named Philotheos Bryennios was studying in a monastery in Constantinople when he came across an unusual ancient manuscript.1 It was called The Teaching of the Twelve Apostles or the Didache and was unlike anything most people had ever seen before. It contained instructions on how early Christians, perhaps as early as the end of the first century, were to perform ordinances and how the church was to conduct itself.
Dan Reynolds' own complex relationship with The Church of Jesus Christ of Latter-day Saints has grown more complicated since last summer’s Loveloud festival. He has heard from church members who felt he criticized the church in his documentary film "Believer." But Reynolds said he has been in regular contact with people at church headquarters since the first LoveLoud and called their patience with him "eye-opening."
A study published today in Nature Genetics co-authored by BYU geneticist Mary Davis identifies biomarkers in multiple sclerosis patients that indicate if they are more likely to develop liver injury (a serious side effect) during the most common type of MS treatment. The research provides a path for clinicians to test patients prior to treatment so they can prevent drug-induced liver damage in at-risk patients.